Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL). It begins in the mantle zone (the outer area of small lymphocytes surrounding a lymphatic nodule). Sometimes MCL cells enter the lymphatic channels and blood to spread to other lymph nodes or tissues (eg, bone marrow, liver, or gastrointestinal tract).
MCL accounts for approximately 5% of all NHL cases in the United States and Europe. Incidence is estimated at 4 to 8 people per million, per year. While rare, MCL is an aggressive form of NHL that is often diagnosed at an advanced stage. MCL is incurable in most people, however, prompt diagnosis and treatment can reduce disease progression and may result in complete remission for years.
In addition, there have been major advancements in treatment options in recent years. New drug approvals include Bruton Tyrosine Kinase (BTK) inhibitors, ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib), proteosome inhibitors (bortezomib), and cellular therapies (ie, CAR T-cell therapies).
If you have any questions about this project, please contact the ACCC Provider Education department.
This video series aims to provide an overview of the latest treatments available for patients with relapsed or refractory mantle cell lymphoma. The series covers recent trial results, potential new therapies, and an analysis of considerations to bear in mind when deciding on treatment options. The series will also include a case study presentation and discussion between panelists. The series will cover:
In this video, Dr. John Burke provides a brief overview of relapsed/refractory mantle cell lymphoma. He notes that mantle cell lymphoma is a relatively uncommon subtype of non-Hodgkin’s lymphoma, which is often diagnosed at advanced stages. Dr. Burke explores recent advancements in treating relapsed/refractory mantle cell lymphoma, including BTK inhibitors. He also examines chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma, focusing on patient eligibility, timing of therapy, and overall response rates. Although bispecific antibodies are not yet approved for mantle cell lymphoma, Dr. Burke reviews the results of early-phase trials. Finally, he reviews a novel BCL-2 inhibitor and highlights combination therapies from recent clinical trials, along with an additional overview of adverse effects.
Dr. Jeff Sharman discusses BTK inhibitors in this video, focusing on progression-free survival and overall survival based on lines of therapy. He reviews findings from clinical studies, including the withdrawal of ibrutinib from the mantle cell lymphoma market. Dr. Sharman also provides an overview of the adverse effects and toxicity profiles for each BTK inhibitor, taking into account comorbidities and prior treatments. Additionally, he covers BTK resistance and non-covalent BTK inhibitors that are being investigated for use in relapsed/refractory mantle cell lymphoma.
In a collaborative discussion, Kirollos Hanna, Dr. Jeff Sharman, and Dr. John Burke reviewed patients who have been newly diagnosed with or have relapsed mantle cell lymphoma. Dr. Sharman discussed the expected initial management, as well as the factors that healthcare providers need to consider when treating patients with mantle cell lymphoma. The case studies reviewed included patients of varying ages, extent of disease, and comorbidities. Drs. Sharman and Burke also reviewed the recent clinical trials that were discussed in prior presentations and how to apply those in clinical practice when deciding on the treatment options for patients with mantle cell lymphoma.
With recent advancements in therapy options for mantle cell lymphoma (MCL) and so few patients presenting with relapsed or refractory (R/R) disease in community settings, hematologists and oncologists are challenged to stay current on the latest targeted therapies. In response to this need, ACCC has developed this tip sheet to provide a snapshot of the latest information in treating patients with MCL, especially with R/R disease.
